Expensive brain-cancer drug no longer an option under Medicare
CBSN
Brain-tumor experts and patient advocates are among those decrying a decision by the seller of a cancer drug to exit a federal discount program for Medicare patients, leaving some unable to afford a treatment that can run as much as $1,000 a capsule.
The move by Miami-based NextSource Biotechnology means the drug Gleostine no longer qualifies for Medicare Part D drug assistance, meaning there is one fewer option of a handful of approved chemotherapies. "There are lots of people right now who are not getting the drug," and some will likely die as a result, Henry S. Friedman, a neuro-oncologist and professor of neurosurgery at Duke University School of Medicine, told CBS MoneyWatch. "There are patients who can't afford the drug, and other drugs may not be as effective."Two Native Hawaiian brothers who were convicted in the 1991 killing of a woman visiting Hawaii allege in a federal lawsuit that local police framed them "under immense pressure to solve the high-profile murder" then botched an investigation last year that would have revealed the real killer using advancements in DNA technology.
In one of his first acts after returning to the Oval Office this week, President Trump tasked federal agencies with developing ways to potentially ease prices for U.S. consumers. But experts warn that his administration's crackdown on immigration could both drive up inflation as well as hurt a range of businesses by shrinking the nation's workforce.
Meta is denying claims circulating on social media that it forced Facebook and Instagram users to follow President Trump's official accounts, saying the changes some users noticed were standard practices tied to the transition of the POTUS account from the previous administration to the incoming one.